EN DE
Watch PegBio Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

PegBio Co Ltd (2565) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of PegBio Co Ltd stock HK$2.70, price HK$3.25, that is 16.9% below the price, quality 46 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

PC PegBio Co Ltd logo Thin data Nov 10, 2026

PegBio Co Ltd

2565 · HK

Expensive (fair value 17% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Ranks above peers (4/6) 
Quality 46/100 
Fair value HK$2.70 · Overvalued 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 5/100
Thin data 
Estimate
Watch PegBio Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$74.65 HK$3.08 Fair Value HK$2.70 May 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

18‑month range HK$3.08 – HK$74.65 · fair‑value band HK$2.02 – HK$3.37 · the HK$3.25 price screens above the HK$2.70 fair value. As of Nov 10, 2026.

Follow PegBio Co in your weekly email

Every Wednesday you see whether PegBio Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity.

Show moreShow less

The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity.

It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia.

Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity.

PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.

Stock analysis

PegBio Co Ltd (2565) currently trades at HK$3.25, while our estimate is HK$2.70, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$2.02 (bear) to HK$3.37 (bull), the price of HK$3.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

PegBio Co Ltd reported revenue of 0 CNY in FY2025 versus 0 CNY in FY2022. Reported net income was −208M CNY in FY2025.

Key figures

Market cap HK$1.3B (≈ $162M) Micro · Return on equity −126% · Return on assets (EBIT) −77.8% (4-year average) · Operating margin 1,800% · Revenue (TTM) −HK$11.4M · Free cash flow −HK$156M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 96% below its 52-week high and 6% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −17%, 2565 screens richer than that median.

Fair Value

Bear HK$2.02 Fair Value HK$2.70 Bull HK$3.37
Price HK$3.25 · Downside -16.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 85
Debt, balance sheet and risk of trouble
Investment 37
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2565 screens overvalued: fair value 17% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare PegBio Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 4/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −16.9% · Above median
Profitability
Return on assets −34.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.36× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 2565
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs 2565
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 2565
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 2565
argenx SE ARGX $960.04 $908.40 −5% vs 2565
CSL Limited CSL A$202.92 A$185.51 −9% vs 2565
Moderna, Inc MRNA $223.37 $139.99 −37% vs 2565
Roivant Sciences Ltd ROIV $39.53 $19.47 −51% vs 2565
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 2565
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 2565

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

PegBio Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "PegBio Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2565

Frequently asked questions

Is PegBio Co Ltd (2565) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$2.70 versus a price of HK$3.25, about 17% lower (overvalued).
What is the fair value of 2565?
Our estimate for PegBio Co Ltd is HK$2.70 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$3.25.
What is the quality score of 2565?
PegBio Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for PegBio Co Ltd (2565)?
Our calculated price target is the estimate of HK$2.70 (as of Nov 10, 2026). Cautious scenario HK$2.02, optimistic scenario HK$3.37. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the PegBio Co Ltd stock forecast for 2026?
Our estimate puts fair value at HK$2.70, about 17% lower versus a price of HK$3.25 (overvalued). Cautious scenario HK$2.02, optimistic scenario HK$3.37. The calculation is refreshed regularly with new filings.
What is the intrinsic value of PegBio Co Ltd (2565)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For PegBio Co Ltd it is HK$2.70 per share (as of Nov 10, 2026), against a price of HK$3.25.
Is PegBio Co Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2565 trades above its calculated fair value: price HK$3.25, fair value HK$2.70, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2565?
No. The price is what the market pays today (HK$3.25); the fair value is what the company's own numbers justify (HK$2.70). For PegBio Co Ltd the two are HK$0.5500 per share apart. That gap is exactly why we show both numbers side by side.
How much is PegBio Co Ltd worth?
The market values PegBio Co Ltd at about HK$1.3B (market capitalisation, as of Nov 10, 2026). Per share that is HK$3.25; our models calculate a fair value of HK$2.70 per share.
What do the bullish and bearish scenarios say about 2565?
Our models span a range for PegBio Co Ltd: cautious scenario HK$2.02, base HK$2.70, optimistic HK$3.37 per share (as of Nov 10, 2026, price HK$3.25). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of PegBio Co Ltd (2565)?
Balance-sheet figures for PegBio Co Ltd (as of Nov 10, 2026): return on equity −125.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 2565 from its 52-week high?
PegBio Co Ltd trades at HK$3.25, about 96% below its 52-week high of HK$74.65 and 6% above the low of HK$3.08 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.70 is for.
Which stocks are comparable to PegBio Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is PegBio Co Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$3.25, calculated fair value HK$2.70 (−17%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. PegBio Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of PegBio Co Ltd (2565)?
The closing price on Nov 13, 2026 was HK$3.25. Our estimate is HK$2.70, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with PegBio Co Ltd right now?
Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of PegBio Co Ltd

How large is the market capitalisation of PegBio Co Ltd (2565)?
The market capitalisation of PegBio Co Ltd is HK$1.3B (≈ $162M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of PegBio Co Ltd (2565)?
The return on equity (ROE) of PegBio Co Ltd is −126% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of PegBio Co Ltd (2565)?
On an EBIT basis the return on assets of PegBio Co Ltd is −77.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of PegBio Co Ltd (2565)?
The operating margin of PegBio Co Ltd is 1,800% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does PegBio Co Ltd (2565) generate?
PegBio Co Ltd generates revenue of −HK$11.4M (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How much free cash flow does PegBio Co Ltd (2565) generate?
The free cash flow of PegBio Co Ltd is −HK$156M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch PegBio Co Ltd in the live analysis

One click puts PegBio Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.